# Harmony Biosciences Reports Record Q2 2026 Revenue and First Clinical Data for Orexin-2 Agonist BP-205

> clinical trial · REPORTED · 2026-08-04

Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, beating analyst EPS estimates of $0.88 with $1.28 diluted EPS, and shares surged nearly 10%. The company also released Phase 1 single ascending dose data for BP-205, its orexin-2 receptor agonist, showing favorable pharmacokinetics and a clean safety and tolerability profile, with Phase 1b and Phase 2 trials advancing through 2027.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences is a commercial-stage pharmaceutical company developing and commercializing therapies for rare neurological diseases, with WAKIX (pitolisant) approved for narcolepsy-associated cataplexy and a pipeline targeting CNS disorders.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-announces-record-q2-2026-revenue-and-shares

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.